Glaukos Co. (NYSE:GKOS) Shares Sold by Rhenman & Partners Asset Management AB

Rhenman & Partners Asset Management AB trimmed its position in shares of Glaukos Co. (NYSE:GKOS - Free Report) by 67.1% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 36,531 shares of the medical instruments supplier's stock after selling 74,469 shares during the quarter. Rhenman & Partners Asset Management AB owned 0.07% of Glaukos worth $5,477,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also bought and sold shares of the company. Landscape Capital Management L.L.C. bought a new position in shares of Glaukos during the fourth quarter valued at approximately $461,000. Geode Capital Management LLC lifted its position in shares of Glaukos by 2.2% during the fourth quarter. Geode Capital Management LLC now owns 1,197,215 shares of the medical instruments supplier's stock worth $179,555,000 after purchasing an additional 25,199 shares during the last quarter. Alliancebernstein L.P. boosted its stake in shares of Glaukos by 1,235.4% during the fourth quarter. Alliancebernstein L.P. now owns 816,153 shares of the medical instruments supplier's stock valued at $122,374,000 after purchasing an additional 755,035 shares during the period. O Shaughnessy Asset Management LLC grew its holdings in shares of Glaukos by 4.6% in the fourth quarter. O Shaughnessy Asset Management LLC now owns 4,410 shares of the medical instruments supplier's stock worth $661,000 after purchasing an additional 192 shares during the last quarter. Finally, Schroder Investment Management Group grew its holdings in shares of Glaukos by 213.9% in the fourth quarter. Schroder Investment Management Group now owns 10,259 shares of the medical instruments supplier's stock worth $1,538,000 after purchasing an additional 6,991 shares during the last quarter. Institutional investors own 99.04% of the company's stock.

Remove Ads

Insider Buying and Selling

In other Glaukos news, insider Tomas Navratil sold 3,416 shares of the business's stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $147.14, for a total value of $502,630.24. Following the completion of the transaction, the insider now directly owns 72,437 shares of the company's stock, valued at approximately $10,658,380.18. The trade was a 4.50 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Alex R. Thurman sold 1,520 shares of the company's stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $106.84, for a total value of $162,396.80. Following the completion of the sale, the chief financial officer now owns 53,431 shares in the company, valued at approximately $5,708,568.04. This represents a 2.77 % decrease in their position. The disclosure for this sale can be found here. 6.40% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of equities analysts have commented on GKOS shares. Mizuho upgraded shares of Glaukos from a "neutral" rating to an "outperform" rating and upped their target price for the stock from $140.00 to $200.00 in a research note on Wednesday, February 19th. Needham & Company LLC raised their price objective on Glaukos from $149.00 to $176.00 and gave the stock a "buy" rating in a report on Friday, February 21st. Citigroup upgraded Glaukos from a "neutral" rating to a "buy" rating and upped their target price for the stock from $132.00 to $162.00 in a report on Wednesday, December 11th. Stifel Nicolaus raised their price target on Glaukos from $153.00 to $175.00 and gave the company a "buy" rating in a research note on Tuesday, December 31st. Finally, Wells Fargo & Company upped their price objective on shares of Glaukos from $153.00 to $160.00 and gave the stock an "overweight" rating in a research note on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Glaukos currently has a consensus rating of "Moderate Buy" and a consensus price target of $163.25.

Glaukos Stock Down 4.9 %

Glaukos stock traded down $4.59 during midday trading on Thursday, reaching $88.96. The company's stock had a trading volume of 355,555 shares, compared to its average volume of 626,409. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71. The stock has a market capitalization of $5.03 billion, a P/E ratio of -30.95 and a beta of 0.88. The stock's 50-day simple moving average is $116.82 and its 200-day simple moving average is $133.18. Glaukos Co. has a 52-week low of $77.91 and a 52-week high of $163.71.

Glaukos (NYSE:GKOS - Get Free Report) last released its earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.02). The company had revenue of $105.50 million for the quarter, compared to analysts' expectations of $100.72 million. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. On average, sell-side analysts expect that Glaukos Co. will post -1.08 EPS for the current year.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.